'Venereal Disease:' Charlie Munger Says Bitcoin And Other Cryptos Are 'Beneath Contempt'

Berkshire Hathaway Inc. (NYSE: BRK-A) (NYSE: BRK-B) Vice Chairman Charlie Munger has again shown his dislike for Bitcoin BTC/USD and other cryptocurrencies, calling them a “venereal disease.”

What Happened: Speaking at the Daily Journal Corp.’s DJCO annual meeting on Wednesday, Munger said he was proud of the fact that he avoided investing in cryptocurrencies.

“It is like some venereal disease or something. I regard it as beneath contempt,” Munger, who is the chairman of the Daily Journal as well as the long-time business partner of legendary investor Warren Buffett, said.

Munger also claimed cryptocurrencies are mainly useful for kidnappings, extortions and tax evasion, adding that he admired the Chinese for banning it.

He welcomed the idea of the U.S. Federal Reserve launching its own digital currency.

See Also: How To Buy Bitcoin (BTC)

Why It Matters: Munger has long been a critic of cryptocurrencies, having previously called Bitcoin a “turd” and an “artificial substitute” for gold.

Buffet too had called the apex cryptocurrency “rat poison squared” in 2020.

Daily Journal and Berkshire Hathaway have large investment positions in Bank of America Corp. BAC and other large banks that have exposure to cryptocurrencies in one form or the other.

Price Action: Daily Journal shares closed 1.8% higher in Wednesday’s regular trading session at $327.85 and further rose 4.2% in the after-hours session to $341.65.

Bitcoin is down 0.4% during the past 24 hours, trading at $43,974.23 at press time.

Read Next: Bitcoin, Ethereum, Dogecoin Trade Flat After Fed Minutes Released — Why The Apex Coin Looks Very Healthy To This Analyst

Photo: Courtesy of Nick via Wikimedia

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CryptocurrencyNewsSmall CapMarketsBitcoinCharlie MungerWarren Buffett
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!